CHGB and Alzheimer disease: A reduction in this transcription factor could potentially result in several of the observed proteomics changes in AD [specifically underlying the reduced levels of Angiotensinogen (AGT), Complement factor D (CFAD), SCG1, Collagen alpha-1(I) chain (CO1A1), Peptidyl-prolyl cis–trans isomerase B (PPIB), SCG2, SODC and Extracellular superoxide dismutase (SODE) expression].